Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

Arcadian Trial Logo

FULL TITLE

A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination with Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer

 

SHORT TITLE

ARCADIAN: Atovaquone with Radical ChemorADIotherapy in locally Advanced NSCLC

 

The ARCADIAN trial has received Green Light approval from OCTRU and subsequently opened to recruitment at its first site in Oxford.

Funded by CRUK, ARCADIAN aims to investigate whether the drug atovaquone can be safely given to patients undergoing chemoradiotherapy for Non-Small Cell Lung Cancer (NSCLC).

Atovaquone has previously been shown to reduce tumour hypoxia, a state which can cause resistance to traditional cancer treatments. If the study shows that it is safe to administer atovaquone with chemoradiotherapy, further studies would be planned to assess the efficacy of this combination treatment.

 

Find out more on the Department of Oncology website: https://www.oncology.ox.ac.uk/about-us/overview/clinical-trials/clinical-trial-portfolio/arcadian

Similar stories

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Emergency departments to use the FORCE pathway for wrist fractures in children

New research from the University of Oxford has shown that doctors can simplify treatment for the most common fracture in children, reducing NHS costs.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.